Caris Life Sciences, Inc. CAI revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Caris Life Sciences, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $812M, 100.0% of the filed sum (+97.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$812M100.0%+97.0% yoy
Members sum to the consolidated $812M for this period.
- Reportable Segment$45.1M100.0%-117.5% yoy
Members sum to the consolidated $45.1M for this period.
- Molecular Profiling Services$767M94.4%+119.6% yoy
- Pharma Research And Development Services$45.3M5.6%-28.2% yoy
Members sum to the consolidated $812M for this period.
- United States$801M98.7%+99.4% yoy
- Outside the United States$10.6M1.3%+2.1% yoy
Members sum to the consolidated $812M for this period.
- Molecular Profiling Services$211M97.5%+84.8% yoy
- Pharma Research And Development Services$5.37M2.5%-21.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.